GlassScriptPhysician profile
Kristen Smith
NPI 1851633275
$14,314.27
in general payments reported to CMS, 2019-2025
63 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,597 · 2022: $2,672 · 2023: $2,051 · 2024: $4,147 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,319 · Travel and Lodging: $695 · Education: $30.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,318.85 |
| Travel and Lodging | $695.02 |
| Education | $30.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,195.19 | 2021-2025 | |
| Livanova USA, INC. | $2,016.19 | 2021-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $1,443.28 | 2021-2025 | Nayzilam, Rystiggo, Fintepla |
| Mdd US Operations, LLC | $1,222.47 | 2021-2025 | Gocovri, Apokyn, Gocovri |
| Sk Life Science, INC. | $666.89 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $655.51 | 2021-2024 | Ajovy, Austedo, Austedo Xr |
| Neurelis, INC. | $488.65 | 2021-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $391.73 | 2022-2025 | |
| Lilly USA, LLC | $332.07 | 2021-2024 | Reyvow, Emgality, Amyvid |
| Amneal Pharmaceuticals LLC | $321.22 | 2021-2023 | Lyvispah, Rytary |
| Alexion Pharmaceuticals, INC. | $278.68 | 2021-2025 | Ultomiris, Koselugo |
| Biohaven Pharmaceuticals, INC. | $277.82 | 2021 | |
| Supernus Pharmaceuticals, INC. | $212.76 | 2021-2025 | Qelbree |
| Azurity Pharmaceuticals, INC. | $211.76 | 2023-2025 | Horizant, Horizant, Zonisade |
| Catalyst Pharmaceuticals, INC. | $211.61 | 2023-2025 | Fycompa |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.